Filing Details

Accession Number:
0001640455-18-000024
Form Type:
4
Zero Holdings:
No
Publication Time:
2018-03-07 19:00:36
Reporting Period:
2018-03-05
Accepted Time:
2018-03-07 19:00:36
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1640455 Jounce Therapeutics Inc. JNCE Biological Products, (No Disgnostic Substances) (2836) 454870634
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1693456 Elizabeth Trehu C/O Jounce Therapeutics, Inc.
780 Memorial Drive
Cambridge MA 02139
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2018-03-05 4,545 $4.02 4,545 No 4 M Direct
Common Stock Disposition 2018-03-05 3,179 $21.24 1,366 No 4 S Direct
Common Stock Disposition 2018-03-05 1,366 $22.11 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2018-03-05 4,545 $0.00 4,545 $4.02
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
246,805 2025-11-12 No 4 M Direct
Footnotes
  1. The sales reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 8, 2017. The Reporting Person exercised no discretion with respect to the trades.
  2. Represents the weighted average share price of an aggregate total of 3,179 shares sold in the price range of $20.86 to $21.70 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  3. Represents the weighted average share price of an aggregate total of 1,366 shares sold in the price range of $21.98 to $22.22 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
  4. 25% of the option shares vested and became exercisable on November 3, 2016 and the remainder of the option shares vest and become exercisable in 12 quarterly installments thereafter.